Posts found in:
Grantees

Tait D. Shanafelt, MD

Tait D. Shanafelt, MD

Published: Jun 13, 2018   |   Author: Michele Keene   |   No Comments

Interrupting Survival Signals in Early Stage CLL: A Maneuver to Prevent Progression Chronic Lymphocytic leukemia (CLL) is the most common sub-type of leukemia in the U.S. and is presently an incurable disease. Building on his preclinical and clinical observations, Dr. Shanafelt has opened a clinical trial of green tea extract in capsule form for patients […]

Read more
Steven R. Pirie-Shepherd, PhD

Steven R. Pirie-Shepherd, PhD

Published: Jun 13, 2018   |   Author: Michele Keene   |   No Comments

Cleaved Serpins as Anti-Angiogenic Therapeutics in the Treatment of Cancer Angiogenesis-the formation of new blood vessels-is critical to the growth and survival of many tumors, and occurs at a much accelerated pace in tumors compared to normal tissue. Angiogenesis inhibitors, investigational agents that starve out tumors by cutting off their blood supply, hold out great […]

Read more
Steven D. Mittelman, MD, PhD

Steven D. Mittelman, MD, PhD

Published: Jun 13, 2018   |   Author: Michele Keene   |   No Comments

Overcoming L-Asparaginase Resistance Caused by Adipocyte Production of Glutamine Overweight leukemia patients are harder to cure than thin patients. We found that an important chemotherapy, L-asparaginase, does not work as well in overweight mice compared to thin mice. Fat cells produce glutamine, which we think may help leukemia cells resist this important medicine. We will […]

Read more
Juliet N. Barker, MBBS (Hons), FRACP

Juliet N. Barker, MBBS (Hons), FRACP

Published: Jun 13, 2018   |   Author: Jen Ranieri   |   No Comments

Double Unit Grafts for the Treatment of High Risk Hematologic Malignancies Umbilical cord blood (UCB) collected from healthy newborns is an alternative source of blood-forming stem cells and UCB transplant is a very promising treatment strategy in children with leukemia. However, early experience in UCB transplant in adults has not been successful in many patients […]

Read more
Stephen X. Skapek, MD

Stephen X. Skapek, MD

Published: Jun 13, 2018   |   Author: Michele Keene   |   No Comments

Functional and Genetic Analysis of a Novel RB-Associated Transcriptional Repressor in Human Leukemia and Lymphoma Researchers have identified and studied a gene known as the RB gene that acts as a natural tumor suppressor by regulating cell proliferation (multiplication of cells). Abnormal cell proliferation is one characteristic of cancer, and the inability to “turn off” […]

Read more
Julia L. Glade-Bender, MD

Julia L. Glade-Bender, MD

Published: Jun 13, 2018   |   Author: Jen Ranieri   |   No Comments

A Pilot Study of Investigating the Effects of Glutamine and Vincristine-induced Neuropathy in Pediatric Patients with Cancer Patients with cancer are amongst the highest users of complementary/alternative therapies. Recent surveys have found 84% of pediatric oncology patients on standard anticancer protocols are taking some form of complementary/alternative medicine. However the safety of these therapies combined […]

Read more
Shari Goldfarb, MD

Shari Goldfarb, MD

Published: Jun 13, 2018   |   Author: Michele Keene   |   No Comments

Reproductive and sexual concerns of young women treated for lymphoma, leukemia and breast cancer Dr. Goldfarb’s team will document the impact of cancer treatment on reproductive and sexual health in young women treated for lymphoma, leukemia and breast cancer.  Premature ovarian failure and sexual dysfunction are serious problems that reduce their quality of life.  They […]

Read more
Jonathan H. Schatz, MD

Jonathan H. Schatz, MD

Published: Jun 13, 2018   |   Author: Jen Ranieri   |   No Comments

Genomics of Peripheral T-Cell Lymphoma Peripheral T-cell lymphoma (PTCL) is a group of rare diseases that collectively comprise 15 percent of lymphomas. The diseases are poorly understood and often have poor prognosis. Memorial Sloan-Kettering Cancer Center has one of the highest volumes of PTCL patients the country. This provides opportunity to study the disease by […]

Read more
Shan Zha, MD, PhD

Shan Zha, MD, PhD

Published: Jun 13, 2018   |   Author: Michele Keene   |   No Comments

The role of ATM kinase in suppression of B cell lymphomas Our lab is interested in understanding how cells sense DNA double stand breaks, integrate cell cycle progression and cellular survival to facilitate precise DNA repair and to prevent cancer-causing transformation. Defects in DNA repair machinery often lead to primary immunodeficiency and increase the risk […]

Read more
Scott A. Armstrong, MD, PhD

Scott A. Armstrong, MD, PhD

Published: Jun 13, 2018   |   Author: Michele Keene   |   No Comments

Epigenetic Programs in MLL-rearranged leukemias The Armstrong lab is using high throughput approaches that assess gene activity and chromosome structure in leukemias. Recent data suggest that certain mutations induce acute myelogenous leukemia (AML) by altering chromosome structure. The proteins that control the abnormal chromatin structure in these leukemias are enzymes (called histone methyltransferases) that present […]

Read more
John M. Timmerman, MD

John M. Timmerman, MD

Published: Jun 13, 2018   |   Author: Jen Ranieri   |   No Comments

Anti-CTLA Monoclonal Antibody Therapy for B Cell Lymphoma Most non-Hodgkin’s B cell lymphomas are resistant to cure with conventional chemotherapy. Paradoxically however, lymphomas are among the most susceptible of human cancers to destruction by immunologic mechanisms (T cells and antibodies). We are seeking to develop new ways to “jump start” the immune system of lymphoma […]

Read more
John F. Gerecitano, MD, PhD

John F. Gerecitano, MD, PhD

Published: Jun 13, 2018   |   Author: Jen Ranieri   |   No Comments

Targeting DNA Repair mechanisms and Tumor Protein Regulation to Treat Patients with Lymphoma Important differences exist between cancerous and normal cells in DNA repair and protein regulation.  Dr. Gerecitano is currently exploiting these differences in three clinical trials: 1) Combining ABT-888, which disables the DNA repair enzyme PARP, with bendamustine, which causes genetic damage that […]

Read more